DUBLIN--(BUSINESS WIRE)--The "Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
The global depression drugs market is expected to grow at a CAGR of 2.5% during 2019-2024.
The growing prevalence of major depressive disorders across the globe is the key factor driving the growth of the market. Depression in adolescents and adults is increasing due to several factors including social isolation, improper dietary habits and work-life imbalance. Furthermore, the increasing geriatric population across the globe that suffers from isolation from family and friends, along with other health-related issues, are also augmenting the growth of the market.
However, there is rising awareness about depression as a psychological issue and methodologies to cure it, which has enhanced the adoption of these drugs among patients of all age groups. Additionally, the emergence of novel techniques for the development of antidepressants with minimal side-effects and prolonged results, along with the acceptance of new medications, is also favoring the market growth. For instance, psychedelics such as ketamine are widely considered to ease the symptoms of depression and provide relief.
Competitive Landscape
The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.
Key Questions Answered in This Report
- How has the global depression drugs market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global depression drugs industry?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the disorder type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the global depression drugs industry?
- What are the key driving factors and challenges in the global depression drugs industry?
- What is the structure of the global depression drugs industry and who are the key players?
- What is the degree of competition in the global depression drugs industry?
Key Topics Covered
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Depression Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Drug Class
5.4 Market Breakup by Disorder Type
5.5 Market Breakup by Drug Type
5.6 Market Breakup by Distribution Channel
5.7 Market Breakup by Region
5.8 Market Forecast
6 Market Breakup by Drug Class
6.1 Atypical Antipsychotics
6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
6.4 Central Nervous System (CNS) Stimulants
6.5 Tricyclic Antidepressants
6.6 Monoamine Oxidase Inhibitors
6.7 Others
7 Market Breakup by Disorder Type
7.1 Major Depressive Disorder
7.2 Obsessive-Compulsive Disorder
7.3 Generalized Anxiety Disorder
7.4 Panic Disorder
7.5 Others
8 Market Breakup by Drug Type
8.1 Generic Drugs
8.2 Branded Drugs
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
9.4 Others
10 Market Breakup by Region
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Middle East and Africa
10.5 Latin America
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porter's Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Otsuka Pharmaceutical
15.3.2 Pfizer
15.3.3 Eli Lilly and Company
15.3.4 AstraZeneca
15.3.5 Novartis
15.3.6 Bristol-Myers Squibb
15.3.7 GlaxoSmithKline
15.3.8 Takeda Pharmaceutical Company
15.3.9 Allergan
15.3.10 Johnson & Johnson
15.3.11 Zhejiang NHU Company Ltd.
15.3.12 Sebela Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/e1wod0
